D.E. Shaw & Co
CADL icon

D.E. Shaw & Co’s Candel Therapeutics CADL Stock Holding History

D.E. Shaw & Co’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,867
Closed -$55K – 5360
2022
Q1 		$55K Buy
10,867
+745
+7% +$3.7K ﹤0.01% 5123
2021
Q4 		$79K Buy
+10,122
New +$98.3K ﹤0.01% 5117

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's CADL Position: Q2 2022 in Review

D.E. Shaw & Co sold out of Candel Therapeutics (CADL) in Q2 2022, closing a stake of 10,867 shares — an estimated $55K sold.

D.E. Shaw & Co first reported a position in CADL in Q4 2021 and held it in 2 quarters. The position peaked at $79K in Q4 2021. 23 funds tracked by Wall St. Rank hold CADL as of Q2 2022.

  • D.E. Shaw & Co reported no remaining Candel Therapeutics position as of Q2 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 10,867 Candel Therapeutics shares in Q2 2022, an estimated $55K.
  • D.E. Shaw & Co first reported a position in Candel Therapeutics in Q4 2021 and held it in 2 quarters.
  • D.E. Shaw & Co's Candel Therapeutics position peaked at $79K in Q4 2021.
  • 23 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2022.

Based on D.E. Shaw & Co's 13F filing for Q2 2022, filed 15 Aug 2022.